Sylentis Eyes Second Part of Phase I/II Trial for Glaucoma Rx, Searches for Partners

The first portion of the study was completed a few weeks ago, according to a company official, and the drug has been shown to be safe and well tolerated.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories